BioWorld MedTech

Oct. 21, 2011

Abbott reports plan to split into two separate companies

Two companies are better than one or so Abbott (Abbott Park, Illinois) has decided. The company plans to split into two publicly traded companies, one in diversified medical products and the other in research-based pharmaceuticals. Read More

Crimson's research memo details total cost of device documentation

International report: Cook's Spectrum Turbo-Ject PICC available in Canada

Washington roundup: FDA urged to tread lightly on artificial pancreas guidance

Agreements/contracts: Zimmer to distribute Benvenue's Kiva VCF

Deals roundup: Misonix sheds lab, forensic business for $1.5 million

Financings roundup: Sphere Medical looking to raise $24 million in an IPO

HIT roundup: Segasist wins first FDA 510(k) for Segasist P-AC

People in the News

Med-Tech Notes: RF Surgical works with UNC hospitals

Product Briefs

CareFusion initiates Class I recall of EnVe ventilators

MDD's Diagnostic Extra

Today's news in brief

BioWorld

Precision psychiatry beyond, or before, biomarkers

BioWorld

There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...

ADPD 2026: Can we prevent dementia? Scientists quantify it

BioWorld

Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...

First-in-class POLG activator restores mtDNA across mutations

BioWorld Science

Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...

Illustration of Alzheimer's disease in the brain

ADPD 2026: Three inflection points to target Alzheimer’s disease

BioWorld Science

A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...